Diplomat Pharmacy,Inc. (NYSE:DPLO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Time-Based Stock Option Awards

On December5, 2016, the Board of Directors of Diplomat
Pharmacy,Inc. (the Company) approved a form of Stock Option Award
Agreement (Time-Based) (the Option Award Agreement) for options
to be issued from time to time under the Companys 2014 Omnibus
Incentive Plan. Under the terms of the Option Award Agreement,
the Company may issue options to purchase a number of shares of
common stock of the Company (the Option Shares) which will be
earned ratably over a four-year period, with 25% of the options
shares vesting on each anniversary of the initial grant. The new
form of Option Award Agreement is substantially identical to the
form of award for time-vested options previously filed by the
Company with the Securities and Exchange Commission, except that
the Option Award Agreement contains provisions regarding
double-trigger vesting in the case of termination following a
change in control under certain circumstances. The Option Award
Agreement also provides for termination of the award in certain
cases of employment termination without connection to any change
in control event. The Formof Stock Option Award Agreement
(Time-Based) is attached hereto as Exhibit10.1 and is
incorporated herein by reference.

On December5, 2016, the Companys Board of Directors approved the
issuance of time-based option awards to certain employees,
including two of the Companys executive officers in the following
amounts: Paul Urick, its President, 200,000 Option Shares, and
Gary Rice, its Executive Vice President of Operations, 100,000
Option Shares.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits

About Diplomat Pharmacy, Inc. (NYSE:DPLO)

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Company operates through specialty pharmacy services segment. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. Its specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

Diplomat Pharmacy, Inc. (NYSE:DPLO) Recent Trading Information

Diplomat Pharmacy, Inc. (NYSE:DPLO) closed its last trading session down -0.22 at 13.13 with 1,305,106 shares trading hands.